News Center

TOT BIOPHARM won the "outstanding contribution award of science and technology research and development" in the park

发布时间:2019-09-02

On December 20, at the 2018 suzhou industrial park innovation and development conference and jinji lake talent recognition conference, TOT BIOPHARM won the "outstanding contribution award to science and technology research and development". Li yaping, deputy secretary of CPC and mayor of the park; lu xin, member of CPC standing committee and minister of organization department; wu qingwen, member of CPC standing committee and secretary of the party working committee of the park; lu chunyun, deputy mayor of the park; zhou wei, secretary-general of the municipal government attended the event and awarded prizes to the winning enterprises. The meeting was presided over by ding lixin, deputy secretary of the party working committee of the park and director of the management committee. TOT BIOPHARM deputy general manager liu donglian on behalf of the company to receive the award. 
 At present, suzhou industrial park takes scientific and technological innovation as the core strategy of regional development and focuses on building a leading biomedical industry in China. This conference awarded TOT BIOPHARM "outstanding contribution award to science and technology research and development" honorary title, is the company's research and development innovation ability recognition and affirmation. TOT BIOPHARM for many years specializing in anti-tumor drug development, production and marketing. The company has invested heavily in the research and development of anti-cancer drugs for a long time. At present, 4 biological drugs (including ADC drugs coupled with antibodies) and 3 chemical drugs have been approved to enter clinical practice. The products of TOT BIOPHARM involve monoclonal antibodies and antibody coupled drugs, oncolytic virus products, and niche chemical drugs (including liposomes) and other anti-tumor drugs.

TOT BIOPHARM is committed to the development of high technical barriers and economic value of new drug products, to provide patients with the most appropriate and reasonable price of the product portfolio, to make a positive contribution to the global cancer cause.